Transient Ischemic Attack

Clinical Trial Finder

Many patients who experience transient ischemic attacks (TIAs) are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

Optimized Remote Ischemic Conditioning (RIC) Treatment for Patients With Chronic Cerebal Ischemia

Conditions:   Chronic Cerebral Ischemia;   Intracranial Atherosclerosis
Interventions:   Device: Remote ischemic conditioning;   Device: Remote ischemic conditioning;   Device: Remote ischemic conditioning;   Device: Remote ischemic conditioning
Sponsor:   Capital Medical University
Not yet recruiting - verified April 2017

Validation of Predictors of OAC Initiation Using EMR Data

Condition:   Atrial Fibrillation
Interventions:   Drug: Dabigatran etexilate;   Drug: Warfarin
Sponsor:   Boehringer Ingelheim
Recruiting - verified April 2017

Antiplatelet Therapy in Acute Mild-Moderate Ischemic Stroke

Condition:   Ischemic Stroke
Interventions:   Drug: clopidogrel;   Drug: Aspirin
Sponsor:   General Hospital of Shenyang Military Region
Recruiting - verified April 2017

Protocol-guided Rapid Evaluation of Veterans Experiencing New Transient Neurological Symptoms

Conditions:   Transient Ischemic Attack;   Stroke
Intervention:   Other: Quality Improvement Program
Sponsor:   VA Office of Research and Development
Recruiting - verified April 2017

SPRITE - A Feasibility and Pilot Study

Condition:   Cerebrovascular Disorders
Interventions:   Other: 'The Healthy Brain Rehabilitation Manual';   Device: Pedometer;   Procedure: Usual care;   Behavioral: Telephone follow-up
Sponsors:   Queen's University, Belfast;   National Institute for Health Research, United Kingdom
Recruiting - verified April 2017

Safety and Efficacy Study of a Protease Activated Receptor-4 Antagonist Being Tested to Reduce the Chances of Having Additional Strokes or "Mini Strokes"

Condition:   Thrombosis
Interventions:   Drug: BMS-986141;   Drug: Aspirin;   Other: Placebo
Sponsor:   Bristol-Myers Squibb
Completed - verified March 2017

Special Drug Use Investigation of Xarelto for Venous Thromboembolism (VTE)

Condition:   Venous Thromboembolism
Intervention:   Drug: Rivaroxaban (Xarelto, BAY59-7939)
Sponsors:   Bayer;   Janssen Research & Development, LLC
Recruiting - verified April 2017

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Sweden)

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Standard of care drugs
Sponsors:   Bayer;   Janssen Scientific Affairs, LLC
Recruiting - verified April 2017

SONOlysis in Prevention of Brain InfaRctions During Internal Carotid Endarterectomy

Condition:   Internal Carotid Artery Stenosis
Intervention:   Device: sonolysis
Sponsors:   University Hospital Ostrava;   Military University Hospital, Prague;   Vitkovice Hospital, Ostrava;   Masaryk Hospital Usti nad Labem;   České Budějovice Hospital;   University Hospital Hradec Kralove;   University Hospital Pilsen;   County Hospital Liberec, Liberec;   University Hospital, Martin;   Jihlava Hospital, Jihlava;   Na Homolce Hospital;   University Hospital, Motol;   Faculty Hospital Nitra;   University Hospital Olomouc;   University Hospital Kosice;   Tomas Bata Hospital, Czech Republic
Recruiting - verified April 2017

Rivaroxaban Versus Aspirin in Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With Recent Embolic Stroke of Undetermined Source (ESUS)

Condition:   Stroke
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Aspirin (Acetylsalicylic acid, BAY1019036);   Other: Rivaroxaban-Placebo;   Other: Aspirin-Placebo
Sponsors:   Bayer;   Janssen, LP;   Hamilton Health Sciences Cooperation, Population Health Research Institute
Recruiting - verified April 2017

Influence of Stroke on the Composition of Intestinal Microbiota

Conditions:   Stroke;   Transient Ischemic Attack (TIA)
Intervention:  
Sponsors:   Charite University, Berlin, Germany;   Prof. Dr. Ulrich Dirnagl, Experimental Neurology, Charité Berlin, Germany;   Dr. Christian Meisel, Medical Immunology, Charité Berlin, Germany;   PD Dr. Andreas Nitsche, Robert-Koch-Institut, Berlin, Germany
Recruiting - verified April 2017

Essential Hypotension and Allostasis Registry

Conditions:   Blood Pressure;   Depression;   Panic Attack;   Fibromyalgia;   POTS;   Inappropriate Sinus Tachycardia;   Coronary Heart Disease;   Acute Coronary Syndrome (ACS);   Acute Myocardial Infarction (AMI);   Cerebrovascular Disease (CVD);   Transient Ischemic Attack (TIA);   Atrial Fibrillation;   Diabetes Mellitus;   Cancer;   Systolic Heart Failure;   Diastolic Heart Failure;   Chronic Fatigue Syndrome;   Syncope;   Vasovagal Syncope
Intervention:  
Sponsor:   CES University
Recruiting - verified April 2017

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Conditions:   Stroke;   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified April 2017

Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial

Condition:   Ischemic Attack, Transient
Interventions:   Drug: Clopidogrel;   Drug: placebo
Sponsors:   University of California, San Francisco;   Neurological Emergencies Treatment Trials Network (NETT);   Medical University of South Carolina;   The EMMES Corporation
Recruiting - verified April 2017

GORE® HELEX® Septal Occluder / GORE® Septal Occluder for Patent Foramen Ovale (PFO) Closure in Stroke Patients - The Gore REDUCE Clinical Study

Conditions:   Stroke;   Transient Ischemic Attack
Interventions:   Device: GORE® HELEX® Septal Occluder / GORE® Septal Occluder;   Other: Antiplatelet Medical Therapy
Sponsor:   W.L.Gore & Associates
Active, not recruiting - verified April 2017

E-Selectin Nasal Instillation to Prevent Secondary Stroke

Conditions:   Ischemic Attack, Transient;   Transient
Intervention:   Drug: Intransal instillation of E-selectin
Sponsor:   National Institute of Neurological Disorders and Stroke (NINDS)
Not yet recruiting - verified March 23, 2017

Natural History of Stroke: Cause and Development

Conditions:   Nervous System Disease;   Transient Ischemic Attack;   Neurologic Disorders;   Stroke;   Vascular Disease
Intervention:  
Sponsor:   National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified October 5, 2016